Bioequivalence Study of Ezetimibe Tablets After a Single Oral Dose of 10  mg in Healthy Japanese Subjects Under Fasting Conditions

This study compared the pharmacokinetic and safety profiles between a new generic and a branded reference product of 10-mg ezetimibe (EZE) tablets in 24 healthy Japanese male volunteers under fasting conditions, obtaining sufficient evidence for the marketing approval of the new generic product. The bioequivalence study was conducted with an open-label, 2 × 2, single-dose, crossover design in which the test and reference products were administered to volunteers after fasting for ≥10 hours. Blood samples were collected 24 times before to 72 hours after the administration of the investigational drug. We evaluated the peak drug concentration and th e area under the plasma concentration–time curve up to the last measured concentration of EZE, EZEG, and total EZE (EZE + ezetimibe glucuronide [EZEG]). The 90% confidence intervals of the geometric mean ratios for peak drug concentration and area under the plasma concentration–time curve up to the last measured concentration of the test and reference products fell within the bioequivalence limits of 0.80 to 1.25 for EZE, EZEG, and total EZE. The test and reference products were well tolerated, and no adverse events occurred during the study. The test product was bioequivalent to the refer ence product.

Source: Clinical Pharmacology in Drug Development - April 6, 2023 Category: Drugs & Pharmacology Authors: Shigenori Wada, Yoshiyuki Sasagane, Seiya Kagatani, Hiroaki Nakagami Tags: Original Article Source Type: research